Kymera Therapeutics (KYMR) Competitors $42.96 -0.79 (-1.81%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$42.92 -0.04 (-0.09%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. QGEN, VTRS, ASND, BBIO, VRNA, BPMC, LEGN, ROIV, RGC, and ELANShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Roivant Sciences (ROIV), Regencell Bioscience (RGC), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors Qiagen Viatris Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Legend Biotech Roivant Sciences Regencell Bioscience Elanco Animal Health Qiagen (NYSE:QGEN) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership. Do institutionals and insiders believe in QGEN or KYMR? 70.0% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts prefer QGEN or KYMR? Qiagen presently has a consensus target price of $49.40, indicating a potential downside of 1.00%. Kymera Therapeutics has a consensus target price of $59.11, indicating a potential upside of 37.60%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 3.10 Which has higher earnings & valuation, QGEN or KYMR? Qiagen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B5.61$83.59M$0.40124.75Kymera Therapeutics$47.07M59.43-$223.86M-$3.10-13.86 Which has more volatility & risk, QGEN or KYMR? Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Is QGEN or KYMR more profitable? Qiagen has a net margin of 4.68% compared to Kymera Therapeutics' net margin of -409.07%. Qiagen's return on equity of 14.61% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.68% 14.61% 8.80% Kymera Therapeutics -409.07%-30.11%-25.65% Does the media refer more to QGEN or KYMR? In the previous week, Qiagen and Qiagen both had 8 articles in the media. Kymera Therapeutics' average media sentiment score of 1.25 beat Qiagen's score of 0.82 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryQiagen and Kymera Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.85B$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-13.8617.6228.6723.80Price / Sales59.43179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book3.338.508.275.55Net Income-$223.86M-$55.06M$3.24B$259.03M7 Day Performance-6.18%-3.98%-3.69%-4.59%1 Month Performance-3.53%9.59%4.33%4.46%1 Year Performance2.19%6.72%25.95%18.03% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics3.5763 of 5 stars$42.96-1.8%$59.11+37.6%-3.4%$2.85B$47.07M-13.86170News CoveragePositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionQGENQiagen3.3183 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.51B$1.98B127.875,765News CoverageUpcoming EarningsVTRSViatris2.227 of 5 stars$9.26-1.6%$10.40+12.3%-26.3%$11.04B$14.33B-2.9232,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0931 of 5 stars$164.16-2.0%$223.07+35.9%+27.8%$10.24B$393.54M-26.141,017Analyst ForecastBBIOBridgeBio Pharma4.7123 of 5 stars$46.23-0.2%$61.50+33.0%+80.9%$8.79B$127.42M-13.10400Upcoming EarningsAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.1954 of 5 stars$105.09-0.2%$109.00+3.7%+365.2%$8.54B$118.54M-52.5530Positive NewsUpcoming EarningsShort Interest ↑BPMCBlueprint Medicines0.7266 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsLEGNLegend Biotech3.5917 of 5 stars$41.51-4.3%$73.33+76.7%-29.5%$7.97B$627.24M-70.352,609Positive NewsROIVRoivant Sciences1.8472 of 5 stars$11.35-1.7%$16.50+45.4%+6.5%$7.85B$29.05M-45.40860Positive NewsUpcoming EarningsRGCRegencell Bioscience0.0502 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010ELANElanco Animal Health3.8056 of 5 stars$14.59-2.2%$16.17+10.8%+5.9%$7.41B$4.43B19.729,000Positive NewsUpcoming Earnings Related Companies and Tools Related Companies QGEN Competitors VTRS Competitors ASND Competitors BBIO Competitors VRNA Competitors BPMC Competitors LEGN Competitors ROIV Competitors RGC Competitors ELAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
